Heart failure & cardiomyopathies
Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy
Primary result · CV death or HF hospitalizationResult — go to the resultHazard ratio 7.0 95% CI 4.1–12.0Authors' conclusion
We identified and externally validated unique HFrEF subpopulations with shared biological characteristics that differentiated residual risk for cardiovascular death or heart failure hospitalization. GDF-15 was the most important protein used to distinguish the 3 HFrEF phenogroups.
Study context
- Population
- Patients with heart failure and reduced ejection fraction (HFrEF) in the VICTORIA trial
- Participants
- 564 patients
- Comparison
- HFrEF phenogroups 1 to 3
- Primary endpoint
- CV death or HF hospitalization
Methodological detailsunsupervised hierarchical clustering, external validation in BIOSTAT-CHF
- Unsupervised hierarchical clustering
- External validation in BIOSTAT-CHF
Primary result
As reported in the abstract
Hazard ratio
7.0
95% CI 4.1–12.0
P ≤ 0.01
Phenogroup 3vs Phenogroup 1
HR 7.0 (95% CI 4.1–12.0); P ≤ 0.01
Further findings
- Event rate in phenogroup 3, external validation cohort (BIOSTAT-CHF) · 1 year
- 41% · 95% CI 38%–45%
Variable discriminating the phenogroups
- GDF-15 was the most important variable in discriminating the 3 phenogroups in both VICTORIA and BIOSTAT-CHF
Original publication
Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy. Circ Heart Fail. Published 8 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →